Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 26, 2008HepatologyOpen Access

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMichael FriedUniversité Paris-SudTPTeerha PiratvisuthPrince of Songkla UniversityGLGeorge LauSun Yat-sen University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fried et al. (2008) studied this question.

synapsesocial.com/papers/6a85105d39db847d1cde0dddhttps://doi.org/10.1002/hep.22065
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Serum Hbv Dna As A Marker of Efficacy During Therapy for Chronic Hbv Infection: Analysis and Review of the Literature2003 · 278 citations
  2. 2Clinical, Virologic and Histologic Outcome Following Seroconversion From Hbeag to Anti–Hbe in Chronic Hepatitis Type B1986 · 275 citations
  3. 3Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B1996 · 812 citations
  4. 4Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa1997 · 229 citations
  5. 5Which Patients With Chronic Hepatitis B Virus Infection Will Respond to α–Interferon Therapy? A Statistical Analysis of Predictive Factors1989 · 309 citations